Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

27.34 +0.02 (+0.07%)

Streaming Delayed Price Updated: 12:10 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims ↗

February 02, 2026

UK regulators ruled Sanofi breached industry rules over RSV claims in a newspaper interview, following a complaint from Pfizer about Beyfortus promotion.

Via Benzinga

Large Cap Biopharmaceuticals: A Core Position For A Healthcare Portfolio ↗

February 02, 2026

Large-cap biopharma offers stable growth and dividends, outperforming the S&P 500 in early 2026. With Gilead up 46% and Pfizer yielding 6%, the sector remains a key volatility hedge following...

Via Talk Markets

Topics Stocks

Option Volatility And Earnings Report For February 2 - 6

February 02, 2026

Last week we saw a plethora of important earnings results and increased market volatility. This wee should be another busy one with a lot of important companies due to report.

Via Barchart.com

3 Headwinds Facing Pfizer in 2026 ↗

February 02, 2026

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Via The Motley Fool

Topics Intellectual Property

Pfizer Inc (NYSE:PFE) Emerges as a High-Quality Technical Breakout Candidate ↗

January 30, 2026

Via Chartmill

TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗

January 26, 2026

Via Stocktwits

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

February 02, 2026

Via Benzinga

1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

February 01, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow

February 01, 2026

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Via StockStory

Here's Why Pfizer Stock Is Still a Buy ↗

February 01, 2026

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Via The Motley Fool

Topics Intellectual Property

This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? ↗

January 30, 2026

Johnson & Johnson is a picture of stability.

Via The Motley Fool

Topics Intellectual Property

3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗

January 30, 2026

All three can provide you with solid, consistent income.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property World Trade

Should You Buy Guardant Health Before Feb. 19? ↗

January 30, 2026

This genomics stock appears to be at an inflection point.

Via The Motley Fool

Topics Earnings

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗

January 29, 2026

The business may not be as strong as its performance this year suggests.

Via The Motley Fool

3 High-Yield Stocks to Buy Hand Over Fist in January ↗

January 29, 2026

If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.

Via The Motley Fool

Topics Economy

This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years ↗

January 28, 2026

After a years-long revenue drought, there's a light at the end of the tunnel.

Via The Motley Fool

Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility

January 28, 2026

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and...

Via MarketMinute

Topics Economy Government World Trade

FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency

January 28, 2026

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial...

Via TokenRing AI

Topics Artificial Intelligence Economy

What's going on in today's session: S&P500 most active stocks ↗

January 28, 2026

Via Chartmill

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

January 27, 2026

Via Chartmill

The Analyst Verdict: Pfizer In The Eyes Of 7 Experts ↗

January 27, 2026

Via Benzinga

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

They could perhaps see sustained runs beyond this year.

Via The Motley Fool

Why Is Pfizer Stock Rising Tuesday? ↗

January 27, 2026

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the...

Via Benzinga

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug ↗

January 27, 2026

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.

Via Benzinga

Where Will Eli Lilly Be in 10 Years? ↗

January 27, 2026

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Via The Motley Fool

Topics ETFs Intellectual Property

What Are Wall Street Analysts' Target Price for Pfizer Stock?

January 27, 2026

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Via Barchart.com

Topics ETFs

What's going on in today's session: S&P500 most active stocks ↗

January 26, 2026

Via Chartmill

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock ↗

January 26, 2026

Via Benzinga

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.